Johnson & Johnson has announced a $2 billion commitment to expand its manufacturing capabilities in the United States, specifically at FUJIFILM’s new biopharmaceutical site in Holly Springs, North Carolina. The company plans to build a facility of over 160,000 square feet at this location, which is expected to create about 120 new jobs in the state.
In addition to this investment, Johnson & Johnson indicated it will soon announce further plans for advanced manufacturing facilities and expansions at existing U.S. sites. These initiatives are part of the company's strategy to produce most of its advanced medicines domestically.
“Johnson & Johnson has more manufacturing facilities in the U.S. than in any other country, and we continue to strengthen our presence here,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “With the recent signing of the One Big Beautiful Bill Act, we continue to expand our investment in the U.S. to lead the next era of healthcare innovation.”
Earlier this year, Johnson & Johnson revealed it would invest $55 billion over four years toward U.S.-based manufacturing, research and development, and technology.
Construction is ongoing at another company facility in Wilson, North Carolina. When completed, it will employ more than 500 people and is projected to generate around 5,000 construction jobs during development. The company is also investing heavily in research infrastructure focused on areas such as oncology, neuroscience, immunology, cardiovascular disease, and robotic surgery.
The partnership with FUJIFILM in Holly Springs will allow Johnson & Johnson to increase its domestic production capacity further and support thousands of jobs across the country.
The company cautioned that forward-looking statements are subject to risks and uncertainties that could cause actual results to differ from expectations. More information can be found on their website or through filings with the Securities and Exchange Commission.